Antibody Bacteria Clinical Development 
pharmaphorum
SEPTEMBER 28, 2021
New phase 2 data with their VLA15 vaccine shows that antibody responses from an initial three-dose regimen are initially high, although they start to decline after 18 months in adult subjects.
Roots Analysis
FEBRUARY 27, 2024
The firm also has the right to obtain exclusive licenses to the Affimer proteins for clinical development and commercialization. What are Affimers : Affimers are small proteins that target and bind molecules on cellular surfaces in a manner analogous to monoclonal antibodies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MARCH 8, 2021
VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. About VLA 15. burgdorferi naïve volunteers. About Lyme Disease.
The Pharma Data
APRIL 26, 2022
About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.
The Pharma Data
OCTOBER 26, 2020
He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program. AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients.
Pfizer
FEBRUARY 16, 2023
While VLA15 is still under investigation, to date the companies have been encouraged by the data from the Phase 2 clinical studies, which demonstrated strong immunogenicity and acceptable safety and tolerability profiles. 2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.
The Pharma Data
DECEMBER 13, 2020
Both patients experienced disease progression on immunotherapy with anti- PD-1/PDL-1 antibodies prior to enrollment in the study. SYNB1891 is being evaluated in a Phase 1 clinical trial. Results of the SYNB1891 Phase 1 study will be presented at a future medical meeting. Sokolovska, A.,
Expert insights. Personalized for you.
105 
Let's personalize your content